Prelude Therapeutics Incorporated
NASDAQ:PRLD
Overview | Financials
Company Name | Prelude Therapeutics Incorporated |
Symbol | PRLD |
Currency | USD |
Price | 1.02 |
Market Cap | 56,135,869 |
Dividend Yield | 0% |
52-week-range | 0.797 - 6.8 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
Website | https://www.preludetx.com |
An error occurred while fetching data.
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD